126 related articles for article (PubMed ID: 6402571)
21. Dosimetry of 188Re-hydroxyethylidene diphosphonate in human prostate cancer skeletal metastases.
Liepe K; Hliscs R; Kropp J; Runge R; Knapp FF; Franke WG
J Nucl Med; 2003 Jun; 44(6):953-60. PubMed ID: 12791825
[TBL] [Abstract][Full Text] [Related]
22. Assessment of synthetic steroid (Org OD 14): effect on skeletal metabolism by 24-h whole-body retention of diphosphonate.
Fogelman I; Bessent RG; Smith ML; Hart DM; Lindsay R
Maturitas; 1981 Dec; 3(3-4):265-9. PubMed ID: 6801438
[TBL] [Abstract][Full Text] [Related]
23. Biokinetics of bone tracers by means of deconvolution analysis--comparison of 99mTc MDP, 99mTc DPD and 99mTc EHDP.
Knop J; Stritzke P; Kröger E; Schneider C; Wasmus G
Nuklearmedizin; 1982 Aug; 21(4):145-9. PubMed ID: 6216459
[TBL] [Abstract][Full Text] [Related]
24. Relative lesion detection ability of Tc-99m HMDP and Tc-99m MDP: concise communication.
Van Duzee BF; Schaefer JA; Ball JD; Chilton HM; Cowan RJ; Kuni C; Trow R; Watson NE
J Nucl Med; 1984 Feb; 25(2):166-9. PubMed ID: 6233404
[TBL] [Abstract][Full Text] [Related]
25. Studies on diphosphonate kinetics. Part II: Whole body bone uptake rate during constant infusion--a refined index of bone metabolism.
Hyldstrup L; McNair P; Ring P; Henriksen O
Eur J Nucl Med; 1987; 12(12):585-8. PubMed ID: 3107991
[TBL] [Abstract][Full Text] [Related]
26. Computer analysis of Tc-99m DPD and Tc-99m MDP kinetics in humans: concise communication.
Mele M; Conte E; Fratello A; Pasculli D; Pieralice M; D'Addabbo A
J Nucl Med; 1983 Apr; 24(4):334-8. PubMed ID: 6834136
[TBL] [Abstract][Full Text] [Related]
27. Technetium-99m complexes of dimethylaminomethylene diphosphonate (DMAD)--II. Biological distributions of 99mTc-DMAD components isolated by anion exchange HPLC.
Holland ME; Bugaj J; Heineman WR; Deutsch E
Int J Rad Appl Instrum B; 1989; 16(3):313-7. PubMed ID: 2497091
[TBL] [Abstract][Full Text] [Related]
28. Age-related alterations in skeletal metabolism--24-hr whole-body retention of diphosphonate in 250 normal subjects: concise communication.
Fogelman I; Bessent R
J Nucl Med; 1982 Apr; 23(4):296-300. PubMed ID: 6802938
[TBL] [Abstract][Full Text] [Related]
29. Diphosphonate bone scanning agents--current concepts.
Fogelman I
Eur J Nucl Med; 1982; 7(11):506-9. PubMed ID: 6217074
[TBL] [Abstract][Full Text] [Related]
30. Measurement of 24-hour whole-body retention of Tc-99mMDP with a thyroid uptake probe: quantitative assessment of metabolic and metastatic bone diseases.
Seto H; Futatsuya R; Ihara F; Kamei T; Furumoto N; Ishizaki Y; Hada M; Kakishita M
Radiat Med; 1984; 2(2):87-92. PubMed ID: 6240671
[TBL] [Abstract][Full Text] [Related]
31. [The kidneys and urinary tracts, as demonstrated by skeletal scintigraphy with 99m technetium-methyl diphosphonate (author's transl)].
Crone-Münzebrock W
Rofo; 1980 Jul; 133(1):75-8. PubMed ID: 6451535
[TBL] [Abstract][Full Text] [Related]
32. Accuracy of 24-h whole-body (skeletal) retention of diphosphonate measurements.
Fogelman I; Bessent R; Scullion JE; Cuthbert GF
Eur J Nucl Med; 1982; 7(8):359-63. PubMed ID: 6811274
[No Abstract] [Full Text] [Related]
33. Technetium-99m-labeled methylene diphosphonate and hydroxyethylidine diphosphonate--biologic and clinical comparison: concise communication.
Rudd TG; Allen DR; Smith FD
J Nucl Med; 1979 Aug; 20(8):821-6. PubMed ID: 120422
[TBL] [Abstract][Full Text] [Related]
34. Clinical comparison of technetium-99m diphosphonate and pyrophosphate in bone scintigraphy: concise communication.
Silberstein EB; Maxon HR; Alexander GW; Rauf C; Bahr GK
J Nucl Med; 1978 Feb; 19(2):161-3. PubMed ID: 203665
[TBL] [Abstract][Full Text] [Related]
35. Skeletal uptake of Tc-99m HEDP in primary hyperparathyroidism.
Fogelman I; Greig WR; Bessent RG; Boyle IT
J Nucl Med; 1977 Oct; 18(10):1040-1. PubMed ID: 409748
[No Abstract] [Full Text] [Related]
36. Gentisic acid: a new stabilizer for low tin skeletal imaging agents: concise communication.
Tofe AJ; Bevan JA; Fawzi MB; Francis MD; Silberstein EB; Alexander GA; Gunderson DE; Blair K
J Nucl Med; 1980 Apr; 21(4):366-70. PubMed ID: 7381564
[TBL] [Abstract][Full Text] [Related]
37. Technetium-99m-methylene diphosphonate--a superior agent for skeletal imaging: comparison with other technetium complexes.
Subramanian G; McAfee JG; Blair RJ; Kallfelz FA; Thomas FD
J Nucl Med; 1975 Aug; 16(8):744-55. PubMed ID: 170385
[TBL] [Abstract][Full Text] [Related]
38. Myeloprotective effects of different amifostine regimens in rabbits undergoing high-dose treatment with 186rhenium-(tin)1,1- hydroxyethylidene diphosphonate (186Re-HEDP).
Brenner W; Kampen WU; Brümmer C; Von Forstner C; Zuhayra M; Muhle C; Czech N; Henze E
Cancer Biother Radiopharm; 2003 Dec; 18(6):887-93. PubMed ID: 14969601
[TBL] [Abstract][Full Text] [Related]
39. High renal activity on bone scintigrams. A sign of hypercalcaemia?
Buxton-Thomas MS; Wraight EP
Br J Radiol; 1983 Dec; 56(672):911-4. PubMed ID: 6228281
[TBL] [Abstract][Full Text] [Related]
40. Observations on computerized quantitative bone scintigraphy in renal osteodystrophy.
de Graaf P; Pauwels EK; Vos PH; Schicht IM; te Velde J; de Graeff J
Eur J Nucl Med; 1984; 9(9):419-25. PubMed ID: 6437823
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
